Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Metadata
Title
Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma
Authors
Yasutsugu Takada
Masanao Kurata
Nobuhiro Ohkohchi
Publication date
01-10-2003
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 5/2003
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-003-0328-6

Other articles of this Issue 5/2003

International Journal of Clinical Oncology 5/2003 Go to the issue

ORIGINAL ARTICLE

Stereotactic radiosurgery (SRS) for multiple metastatic brain tumors: effects of the number of target tumors on exposure dose in normal brain tissues

SPECIAL ARTICLE

Forty years’ experience in surgical treatment for esophageal cancer

ORIGINAL ARTICLE

Laparoscopic radical prostatectomy: initial 30-case experience

CASE REPORT

Pelvic insufficiency fractures after preoperative radiotherapy for rectal carcinoma

ORIGINAL ARTICLE

Eradication and reinfection of human papillomavirus after photodynamic therapy for cervical intraepithelial neoplasia

ORIGINAL ARTICLE

Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits